Navigation Links
Argos Therapeutics Presents Immunosuppression Data for Soluble CD83,at the American Society of Transplantation Congress 2007

on"

-- Abstract #1035: "Immunosuppressive properties of soluble extracellular domain of CD83 on antigen-presenting cells of cynomologous monkey"

About Soluble CD83

CD83 is a glycoprotein expressed on the cell surface of mature dendritic cells (DCs), the most potent stimulators of immune responses. The strong upregulation of this protein during DC maturation suggests that it plays an important functional role in the induction of immune responses. Experimental data demonstrate that soluble CD83 can potently down-regulate immune responses, indicating that it can be developed to treat transplantation rejection and variety of autoimmune disorders. Importantly, data from animal models demonstrate that soluble CD83 exerts its effects without a requirement for chronic administration and does not leave the subject globally immunosuppressed. In April 2006, Argos obtained exclusive therapeutic use rights for CD83 from Beckman Coulter.

About Argos Therapeutics, Inc.

Argos Therapeutics is developing breakthrough immunotherapies that target the unique features of a patient's disease. This new generation of personalized cancer and infectious disease therapeutics, created using the Company's "Arcelis" technology, trains the immune system to recognize and attack the disease. Argos' scientific leadership in RNA-loaded dendritic cells and advanced manufacturing processes provide a platform to tackle virtually all forms of cancers and infectious diseases. www.argostherapeutics.com

Argos is a private biotechnology company headquartered in Research Triangle Park, NC. The Company has clinical trial programs in cancer and human immunodeficiency virus (HIV) and has an ongoing co-development and commercialization alliance with the Pharmaceutical Division of Kirin Brewery Company, Limited.

Contact

MacDougall Biomedical Communications
Chris Erdman, 508-647-0209
or
Argos Therapeutics
Jeff Abbey, 919-287-6308


'"/>




Page: 1 2

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
5. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
6. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
7. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
8. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
9. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Novelos Therapeutics Announces Encouraging Results in Ongoing Phase 2 Ovarian Cancer Trial at Dana-Farber/Partners Cancer Care
Post Your Comments:
(Date:9/2/2014)... MOUNTAIN VIEW, Calif. , Sept. 3, 2014 ... recently completed phase 2 placebo-controlled trial in pediatric ... a statistically significant increase in head circumference.  Decreased ... the disease. Rett syndrome is ... is usually diagnosed by 24 months of age. ...
(Date:9/2/2014)... , Sept. 2, 2014 Astellas has appointed ... property (IP) in the Americas. Kellerman will report directly ... general counsel at Astellas. In his new role, Kellerman ... with the business and manage the region,s intellectual property ... "I am very pleased to welcome Jim to ...
(Date:9/2/2014)... Reportlinker.com announces that a new market ... Asia-Pacific Infusion Therapy Device Market ... The Asia-Pacific ... pumps, syringe infusion pumps, disposable infusion pumps, IV ... are segmented based on the type of displacement ...
Breaking Medicine Technology:Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 2Edison Pharmaceuticals Announces Phase 2 Positive Clinical Results for EPI-743 in Rett Syndrome 3Leading Intellectual Property Counsel, James Kellerman, Joins Astellas as Vice President 2Asia-Pacific Infusion Therapy Device Market 2Asia-Pacific Infusion Therapy Device Market 3Asia-Pacific Infusion Therapy Device Market 4Asia-Pacific Infusion Therapy Device Market 5Asia-Pacific Infusion Therapy Device Market 6Asia-Pacific Infusion Therapy Device Market 7Asia-Pacific Infusion Therapy Device Market 8Asia-Pacific Infusion Therapy Device Market 9Asia-Pacific Infusion Therapy Device Market 10Asia-Pacific Infusion Therapy Device Market 11Asia-Pacific Infusion Therapy Device Market 12Asia-Pacific Infusion Therapy Device Market 13Asia-Pacific Infusion Therapy Device Market 14
... , , , , , , MUMBAI, India, Dec. ... IN, NSE: SUNPHARMA, BSE: 524715) today announced that Glass, Lewis ... that shareholders of Taro Pharmaceutical Industries Ltd. (Pink Sheets: TAROF) ... of directors, including all of its nominees for election or ...
... , SUNNYVALE, Calif., Dec. 22 Arrayit Corporation (OTC Bulletin ... announced that the Company has made a technological breakthrough in ... microarrays, which are tiny glass substrates that contain rows and ... diagnostics. The advance allows highly precise printing of as many ...
Cached Medicine Technology:Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 2Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 3Glass Lewis Advises Taro Shareholders to Hold Taro's Board Accountable for Its Failures 4Arrayit Corporation Announces Manufacturing Breakthrough 2Arrayit Corporation Announces Manufacturing Breakthrough 3
(Date:9/2/2014)... (PRWEB) September 03, 2014 Autumn ... Top10BestSEOHosting.com wants to celebrate the new season with ... of research and announced that Hostgator ( http://secure.hostgator.com/~affiliat/cgi-bin/affiliates/clickthru.cgi?id=seohosts ... hosting suppliers of 2014. , Since 2002 ... hosting provider, and the company’s reputation for reliability ...
(Date:9/2/2014)... pot might be risky business for women, according ... study is the first to demonstrate sex differences ... , Psychology professor Rebecca Craft showed that, thanks ... least 30 percent more sensitive than males to ... in cannabis. Females also develop tolerance to THC ...
(Date:9/2/2014)... Angeles, CA (PRWEB) September 03, 2014 ... health enthusiasts, bodybuilders, and athletes obtain the latest ... its launch. The site, which focuses mainly on ... dedicated to helping individuals increase their workout capacity ... an article available on Top Creatine Monohydrate, Muscle ...
(Date:9/2/2014)... September 02, 2014 Becker's Healthcare ... Officer and Chief Information Officer Strategy Roundtables on ... , Becker's Hospital Review Chief Executive Officer and ... and health system Chief Executive Officers, Chief Financial ... health system executives through high-quality continuing education, ...
(Date:9/2/2014)... Recently, BambooIndustry.com, an excellent company in the bamboo industry, ... bamboo floors to celebrate the coming of autumn. ... the frequent callers, BambooIndustry.com launched a promotion for its ... woven floors, BambooIndustry.com provides many kinds of wonderful items ... woven floors, click lock floors, wide plank floors and ...
Breaking Medicine News(10 mins):Health News:Top10BestSEOHosting.com Celebrates The Coming Of Autumn And Release Reseller Hosting Suppliers Of 2014 2Health News:Estrogen increases cannabis sensitivity 2Health News:Estrogen increases cannabis sensitivity 3Health News:Creatine Monohydrate Reviews Site TopCreatineMonohydrate.com Announces its Launch 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 2Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 3Health News:Becker's Healthcare Announces Hospital CEO and CIO Strategy Roundtables 4Health News:Cheap Strand Woven Bamboo Floors For Autumn On Sale At BambooIndustry.com 2
... Inc. (Nasdaq: MEDQ ), the largest Medical Transcription ... the positive resolution of several material legal matters , ... Investigation , , As ... documents from the United States Department of Justice ("DOJ") on ...
... College of Surgeons (ACS) today recognized the Institute of Medicine ... was released on December 2, 2008, by the IOM Committee ... to Improve Patient Safety. , ... conclusion that further reductions in the mandated 80-hour work week ...
... YORK, Dec. 3, 2008 Forest Laboratories, Inc. (NYSE: ... of an unsolicited mini-tender offer by TRC Capital Corporation (TRC) ... has received a copy of the tender offer to purchase ... stock, which represents less than 1 per cent of its ...
... MAP,Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced ... "Adapting Specialty Pharma Strategy,To Market Conditions" at the 2008 ... at 10:00 am (ET) in New York City. , ... of the panel discussion will be available on the ...
... outperform animal and human derived serum in CHO cell culture. ... ... Cellastim has proven to be a robust replacement for serum derived ... and productivity of CHO cell lines across a variety of chemically ...
... N.J., Dec. 3 As previously announced, HLTH Corporation (Nasdaq: ... (Nasdaq: WBMD ), will be holding their Annual Meetings ... 10, 2008. , , ... the Internet. To listen to the audio webcast of the meetings, ...
Cached Medicine News:Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 2Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 3Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 4Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 5Health News:MedQuist Announces Resolution of the DOJ Investigation and Dismissal of Shareholder Lawsuits 6Health News:American College of Surgeons Comments on Institute of Medicine Report on Resident Duty Hours 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 2Health News:Forest Laboratories Responds To Unsolicited Mini-Tender Offer 3Health News:InVitria's Cellastim Delivers Superior Results in CHO Cell Culture 2Health News:HLTH Corporation and WebMD to Webcast Annual Meetings of Stockholders 2
...
... The mecA ASR contains primers and a FAM-labeled ... bp region of the mecA gene. In addition, ... and DNA for an internal control sequence. This ... and Texas Red reporter dyes such as the ...
... features the ability to use a separate, ... a pre-loaded nitinol filter with a dual-ended ... fully rapid exchange system, the SpideRX Device ... applications:, Carotid Indication - ,The SpideRX Embolic ...
Pefakit PiCT DxS Diluent for Determination of Total Heparin...
Medicine Products: